Antibody-mediated VWF targeting reconstitutes ADAMTS13 metalloproteinase activity and prevents thrombocytopenia in mice
- 1Kyowa Kirin Co., Ltd.
Abstract
ADAMTS13 (a multidomain metalloproteinase) cleaves von Willebrand factor (VWF), thereby preventing the accumulation of ultra-large VWF multimers that promote platelet-rich thrombus formation. Severe ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura (TTP). In immune-mediated TTP (iTTP), anti-ADAMTS13 autoantibodies inhibit ADAMTS13 activity, often by targeting non-catalytic domains that mediate substrate recognition. We developed ADAMTS13 mimetics by fusing the ADAMTS13 metalloproteinase domain to anti-human VWF A2 domain antibodies, aiming to replace native substrate-recognition domains with antibody-mediated substrate targeting while removing major autoantibody-targeted ADAMTS13 domains. The resulting mimetics bound to the recombinant VWF A2 domain and showed proteolytic activity toward both the recombinant VWF A2 domain and FRETS-VWF73 substrate. Kinetic analysis showed that the mimetics had not only lower kcat values than ADAMTS13 but also lower Km values, thereby maintaining overall catalytic efficiency. Importantly, ADAMTS13 mimetics retained VWF A2-cleaving activity in the presence of a spacer domain-directed anti-ADAMTS13 autoantibody both in vitro and in vivo. In an iTTP mouse model, ADAMTS13 mimetics prevented recombinant VWF-induced thrombocytopenia, whereas the parental anti-VWF A2 domain antibody did not. Platelet-preserving activity was also observed in ADAMTS13-deficient mice. In further analyses, some mimetics showed reduced binding to a conformationally restricted VWF A2 domain, resulting in reduced cleavage activity. Antibody binding correlated with platelet recovery in the iTTP mouse model, suggesting that epitope accessibility and antibody-mediated positioning contribute to in vivo activity. These findings demonstrate that antibody-mediated substrate targeting can reconstitute the VWF-cleaving activity of the ADAMTS13 metalloproteinase domain and suggest that ADAMTS13 mimetics represent a potential therapeutic approach for iTTP.
Related
- Programmable Surface Receptor-Mediated Cell Targeting with Designer Antibody-Routed Nanoparticles (DARTs)
- Matrix metalloproteinase-guided targeting of vesicular stomatitis virus to tumors following systemic administration.
- A Cell-based Screening Method Using an Intracellular Antibody for Discovering Small Molecules Targeting Hard-to-drug Proteins
- 211 A discovery-to-therapeutics platform for functional antibody targeting of complex membrane-embedded tumor antigens: validation with claudin family members
- Antibody 3CF5 neutralizes historical and emerging H5Nx influenza viruses by targeting a conserved non-receptor-binding hemagglutinin epitope
BibTeX
@misc{hashimoto2026antibodymediated,
title = {{Antibody-mediated VWF targeting reconstitutes ADAMTS13 metalloproteinase activity and prevents thrombocytopenia in mice}},
author = {A. Hashimoto and Y. Komeda and F. Kiku and M. Oogi and M. Nakano and S. Shiina and H. Imai and Y. Shiraishi and K. Masuda and A. Sano},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.11.750821},
url = {https://www.biorxiv.org/content/10.64898/2026.09.11.750821v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Antibody-mediated VWF targeting reconstitutes ADAMTS13 metalloproteinase activity and prevents thrombocytopenia in mice
AU - A. Hashimoto
AU - Y. Komeda
AU - F. Kiku
AU - M. Oogi
AU - M. Nakano
AU - S. Shiina
AU - H. Imai
AU - Y. Shiraishi
AU - K. Masuda
AU - A. Sano
PY - 2026
DA - 2026/09/11
PB - bioRxiv
DO - 10.64898/2026.09.11.750821
UR - https://www.biorxiv.org/content/10.64898/2026.09.11.750821v1
AB - ADAMTS13 (a multidomain metalloproteinase) cleaves von Willebrand factor (VWF), thereby preventing the accumulation of ultra-large VWF multimers that promote platelet-rich thrombus formation. Severe ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura (TTP). In immune-mediated TTP (iTTP), anti-ADAMTS13 autoantibodies inhibit ADAMTS13 activity, often by targeting non-catalytic domains that mediate substrate recognition. We developed ADAMTS13 mimetics by fusing the ADAMTS13 metalloproteinase domain to anti-human VWF A2 domain antibodies, aiming to replace native substrate-recognition domains with antibody-mediated substrate targeting while removing major autoantibody-targeted ADAMTS13 domains. The resulting mimetics bound to the recombinant VWF A2 domain and showed proteolytic activity toward both the recombinant VWF A2 domain and FRETS-VWF73 substrate. Kinetic analysis showed that the mimetics had not only lower kcat values than ADAMTS13 but also lower Km values, thereby maintaining overall catalytic efficiency. Importantly, ADAMTS13 mimetics retained VWF A2-cleaving activity in the presence of a spacer domain-directed anti-ADAMTS13 autoantibody both in vitro and in vivo. In an iTTP mouse model, ADAMTS13 mimetics prevented recombinant VWF-induced thrombocytopenia, whereas the parental anti-VWF A2 domain antibody did not. Platelet-preserving activity was also observed in ADAMTS13-deficient mice. In further analyses, some mimetics showed reduced binding to a conformationally restricted VWF A2 domain, resulting in reduced cleavage activity. Antibody binding correlated with platelet recovery in the iTTP mouse model, suggesting that epitope accessibility and antibody-mediated positioning contribute to in vivo activity. These findings demonstrate that antibody-mediated substrate targeting can reconstitute the VWF-cleaving activity of the ADAMTS13 metalloproteinase domain and suggest that ADAMTS13 mimetics represent a potential therapeutic approach for iTTP.
ER -